Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

Immunotherapy Clinical Trial

— PROMIT  

Official title:

A Phase 2, Single Arm Study on Dacarbazine (DTIC) Followed by Immunotherapy Re-challenge in Unresectable or Metastatic Melanoma With Primary Resistance to PD-1/PD-L1 or PD-1 + CTLA-4 Blockade

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04225390
• Other study ID #: PROMIT
• Status: Recruiting
• Phase: Phase 2
• Start date: January 13, 2020
• Est. completion date: July 2023

Study information

• Verified date: May 2022
• Source: University of Erlangen-Nürnberg Medical School
• Contact: Lucie Heinzerling, Prof. Dr. MPH
• Phone: +49 (0) 9131- 85 45 804
• Email: lucie.heinzerling[@]uk-erlangen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or metastatic, BRAF wildtype melanoma with primary resistance to anti-programmed-cell-death-1 (PD-1/PD-L1) or PD-1 plus anti-cytotoxic-T-lymphocyte antigen 4 (CTLA-4) blockade therapy. If the activity is clinically meaningful, DTIC could become a new therapeutic option to break primary resistance to immunotherapy.

Description:

PROMIT is a phase 2, single arm, open label study of DTIC followed by combined immune checkpoint blockade (ICB) therapy or PD-1/PD-L1-blockade monotherapy in adult (≥ 18 years) subjects with previously treated, unresectable or metastatic melanoma (Stage III or Stage IV melanoma as per the AJCC staging system). Subjects must be BRAF wildtype and must have shown primary resistance to ICB. Fresh tumor tissue from an unresectable or metastatic site of disease must be available.

Subjects will be treated with DTIC 850 mg/m² day 1 and 21 i.v. (DTIC phase). Afterwards, patients will receive combined ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) 4 times every 3 weeks i.v. OR nivolumab 240 mg every 2 weeks OR pembrolizumab 200 mg every 3 weeks (ICB re-exposure phase; EMA-approved dosing scheme). By the end of the ICB phase, response will be documented (primary endpoint). A safety follow-up for treatment-related adverse events will be performed until 30 days after the last dose of combined ICB. Patients will be followed for survival every 12 weeks after the end of the combined ICB phase (second primary endpoint). Tumor and blood samples will be assessed over the course of the study to evaluate changes in tumor, tumor microenvironment and immune system.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: July 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed metastatic melanoma

2. Progression after checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA-4 blockade)

3. Accessible tumor metastases

4. ECOG 0 or 1

5. Adequate organ function

Exclusion Criteria:

1. Uvea melanoma, mucosal melanoma

2. Previous chemotherapy in metastatic disease

3. Previous response to checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA-4 blockade) in metastatic disease

4. BRAF V600 mutation

5. Active brain metastases

6. Autoimmune disease requiring more than 10 mg prednisolone daily or other immunosuppressive drugs

Related Conditions & MeSH terms

• Immunotherapy

Intervention

Drug:
• Dacarbazine (DTIC)
Dacarbazine powder for IV solution

Locations

Country	Name	City	State
Germany	University Hospital	Erlangen	Bavaria

Sponsors (3)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School	University Hospital Regensburg, Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of participents with CR, PR, SD or PD	A patient is defined as responder if a complete response (CR) or partial response (PR) can be seen. A patient with stable disease (SD) or progressive disease (PD) will be defined as non-responder.	week 14
Secondary	Overall survival (OS)	Overall survival (OS), defined as the time between study inclusion and date of death (any cause). For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive. OS will be followed continuously while subjects are on the study drug and every 12 weeks via phone contact after subjects discontinue the treatment phase.	up to 5 years